HeartBeam, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following is a summary of awards outstanding as of March 31, 2026 and 2025, which are not included in the computation of basic and diluted weighted average shares:


	Three months ended March 31,
	2026		2025
Stock options (excluding exercisable penny stock options)		9,865,643		7,036,576
Restricted stock units		501,488		283,411
Warrants		5,827,035		5,827,031
Total		16,194,166		13,147,018

Schedule of Segment Reporting Information, by Segment

In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:


	Three months ended March 31,
(in thousands)	2026		2025
Employee expenses	$	2,862	$	3,039
Research and Development (excluding employee expenses):
Consulting and professional fees		410		310
Clinical study expenses		143		110
Product development		112		709
Other*		290		304
Total Research and development expense	$	955	$	1,433
Selling, general and administrative expense (excluding employee expenses):
Selling, general and administrative expenses		614		735
Commercialization readiness expenses		285		297
Total Selling, general and administrative expense		899		1,032
Total operating expenses	$	4,716	$	5,504

* Other primarily includes patent, software, product testing and other miscellaneous expenses for the three months ended March 31, 2026 and 2025.